Abstract
Nowadays new findings are emerging regarding the actions and use of cardiovascular drugs [1–12]. Propafenone [13,14], is an antiarrhythmic drug characterized by interaction with cardiac sodium channels and it also exerts consistent beta-blocking action in vitro and variable beta-blocking action in vivo [15]. It works by blocking the fast inward sodium current and slowing the rate of increase of the action potential [16]. Propafenone toxicity manifests mainly with a cardiac impairment in which bradycardia and QRS widening can occur [15,17–20].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
